1. Scrip
  2. >>Business
  3. >>Deals

Allergy Therapeutics Takes First Steps Into Broader Vaccine Field

Licensing Agreement Signed With Saiba And DeepVax

 
• By John Davis

Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.    

Flowers
• Source: Shutterstock

Transitioning its current interests in anti-allergy immunotherapy products into a broader R&D effort, UK-headquartered Allergy Therapeutics plc has extended its tie-up with two European biotechs, Saiba AG and DeepVax GmbH, to include the development of vaccines in therapeutic areas such as cancer and atopic dermatitis. 

Allergy Therapeutics markets a range of allergy desensitization therapies including Pollinex Quattro and Acarovac Plus, and has an existing tie-up with Switzerland’s Saiba and with DeepVax, exclusively licensing their virus-like...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.